Abstract
Nonmalignant portal vein thrombosis (PVT) is a common complication of cirrhosis. Anticoagulation is the first line option, but optimal regimen and dose are still to be determined. Despite many therapeutic options, there are no data regarding the use of fondaparinux (FPX) in the treatment of PVT in cirrhotic patients. The aim of our study was to compare safety and efficacy of FPX and LMWH in the treatment of PVT.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
